title: [Elderly patient with metastatic gallbladder cancer treated by cisplatin, epirubicin and continuous infusion 5-fluorouracil].
abstract: An 80-year-old woman, who was followed as an A-bomb victim, was diagnosed to have advanced gallbladder cancer with liver metastasis on December, 2005. Due to her advanced age, her previous doctor recommended the best supportive care. Therefore, her general condition was good, so we decided to treat her with cisplatin, epirubicin and continuous infusion of 5-fluorouracil(CEF therapy). She was given 5-fluorouracil 500 mg/body per day via continuous infusion on days 1 to 5, cisplatin 50mg body and epirubicin 20mg body on day 1 every 28 days, and these dosages have been reduced. CEF therapy was started from February, 2007. Primary lesion and liver metastasis decreased remarkably after completion of 2 cycles, and we judged it as a complete response. After 10 cycles, lung metastasis was found by CT scan in August, 2007. We tried chemotherapy with gemcitabine as a second-line treatment. The result of gemcitabine was again a progressive disease, so we switched her regimen to S-1 as a third-line treatment on January, 2008. Chemotherapy is continued by the outpatient care now, 25 months after the medical treatment started. The present result suggests that CEF therapy may be useful for metastatic gallbladder cancer.
authors.affiliation: Dept. of Digestive Surgery, Nihon University School of Medicine, Japan.
authors.forename: Nao
authors.initials: N
authors.lastname: Yoshida
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Kochi
authors.forename: Tomoya
authors.initials: T
authors.lastname: Funada
authors.forename: Takao
authors.initials: T
authors.lastname: Mamiya
authors.forename: Riki
authors.initials: R
authors.lastname: Ohkubo
authors.forename: Teruo
authors.initials: T
authors.lastname: Kaiga
authors.forename: Tadatoshi
authors.initials: T
authors.lastname: Takayama
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002945:Cisplatin / Q000627:therapeutic use*; D015251:Epirubicin / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D005706:Gallbladder Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil